₹0 US Stocks A/c opening Fee
SERA PROGNOSTICS INC-A (SERA)
$3.73
Live
Live
Powered by
Performance
$3.73
Day's Range
$3.845
$1.1
52-Week Range
$4.25
| Returns % | |
| 1 month return |  4.1% |
| 3 month return | 228.42% |
| 1 year return | 5.54% |
| 5 year return |  67.98% |
Highlights
| Market Capitalization | 116.6M |
| Book Value | $3.19 |
| Dividend Share | 0.0 |
| Dividend Yield | 0.0% |
| Earnings Per Share (EPS) | -1.0 |
| Wall Street Target Price | 4.63 |
Company Financials
| FY22 | Y/Y Change | |
|---|---|---|
Revenue | 268.0K | ↑ 226.83% |
Net Income | -44.2M | ↑ 26.21% |
Net Profit Margin | -16.5K% | ↑ 26206.59% |
Peers
Analyst Recommendation
Buy
80%
Buy
20%
Hold
0%
Sell
Based on 10 Wall street analysts offering stock ratings for SERA PROGNOSTICS INC-A(by analysts ranked 0 to 5 stars)
Analyst Forecast
What analysts predicted
Upside of 24.13%Current
$3.73
Target
$4.63
Valuation
| Trailing PE | 0.0 |
| Forward PE | 0.0 |
| Price/Book (mrq) | 0.36 |
| Enterprise Value | -48.3M |
| Enterprise Value/Revenue | 128.9 |
| Enterprise Value/Ebitda | 1.05 |
Technicals
| 50 Day MA | 2.68 |
| 200 Day MA | 1.92 |
Institutional Holdings
InterWest Venture Management Co
7.79%
Vivo Capital, LLC
5.98%
Fosun International Ltd
1.79%
CapTrust Financial Advisors
1.22%
Skye Global Management LP
1.07%
Wells Fargo & Co
1.01%
Company Information
Sera Prognostics is a leading women’s health company utilizing its proprietary proteomics and bioinformatics platform to discover, develop and commercialize clinically meaningful and economically impactful biomarker tests, with an initial focus on improving pregnancy outcomes. Sera’s vision is to deliver pivotal and actionable information to pregnant women, their physicians and healthcare payers to significantly improve maternal and neonatal health and to dramatically reduce healthcare costs. Sera’s first commercial product, the PreTRM® Test, is the only broadly clinically validated, commercially available blood-based biomarker test to accurately predict the risk of preterm birth.
| Organization | SERA PROGNOSTICS INC-A |
| Employees | 87 |
| CEO | Dr. Gregory C. Critchfield M.D., M.S. |
| Industry | Healthcare |
Discover more
PERIPHAS CAPITAL PARTNR-CL A
+0.04%▲
HAMILTON LANE ALL-CLASS A
--
Invesco BulletShares 2022 Corporate Bond ETF
+0.02%▲
Pennsylvania Real Estate Investment Trust
--
GORES TECHNOLOGY PARTNERS-A
TCW SPECIAL PURPOSE ACQ-CL A
+0.02%▲
SIMON PROPERTY GROUP ACQUI-A
KL ACQUISITION CORP/MO-CLS A
+0.25%▲
GLENFARNE MERGER CORP-A
--